Markets

Transcenta Collaborates With EirGenix To License HiCB Platform

December 28, 2025 — 08:39 pm EST

Written by RTTNews.com for RTTNews

(RTTNews) - Transcenta Holding Limited (6628.HK) announced it has entered into a strategic collaboration and non-exclusive licensing agreement with EirGenix Inc., a global biopharmaceutical development and manufacturing company.

Under the agreement, Transcenta will grant EirGenix a non-exclusive license to use its Highly Intensified Continuous Bioprocessing (HiCB) platform. This includes highly productive continuous perfusion and integrated hybrid continuous purification process technologies, supported by comprehensive process documentation, know-how, and regulatory packages. Transcenta will receive substantial upfront and milestone payments, along with future royalties tied to the commercial use of the licensed technologies.

The HiCB platform is designed to enhance process efficiency, improve control and product consistency, and significantly reduce manufacturing costs compared to conventional fed-batch processes. The improvements aim to expand global patient access to high-quality, affordable biologics.

Through this collaboration, EirGenix will adopt Transcenta's HiCB platform to advance its biologics development programs and manufacturing operations. The company also plans to apply the platform to serve CDMO clients seeking intensified and continuous manufacturing solutions.

RTTNews
Founded in the late 1990s by Andrew Mariathasan in New York, with the goal of covering Wall Street for a new generation of investors, RTTNews has expanded steadily over the years to become a trusted provider of content for a wide array of subjects across several platforms. RTT's Financial Newswire is relied upon by some of the world's largest financial institutions, including banks, brokerages, trading platforms and financial exchanges.
More articles by this source

Tags

Markets

Latest Articles
Data is currently not available